(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would ...